partnershipHummingbird and Synaffix in $150m ADC dealRational antibody design specialist Hummingbird Bioscience has licenced a cancer target and the modular ADC technology of Dutch Synaffix BV. more ➔
partnershipEthris inks €15m deal with Indian CiplasCipla EU Ltd is going to make an equity investment of €15m in Ethris GmbH, a specialist for respiratory delivery of therapeutic mRNAs. more ➔
MSFirst hints for leukopenia diagnostic in M...Scientists from the University of Basel and the University Hospital Basel have found that two bacterial species may indicate multiple sclerosis-associated lymphopenia. more ➔
PartnershipCollaboration to develop mRNA vaccine agai...CEPI fights the betacoronaviruses by funding Ethris GmbH and DIOSynVax Ltd and their joint effort to advance their work on an mRNA vaccine. more ➔
immunoncologyFirst allogeneic cancer immunotherapy hits...Atara Biotherapeutics Inc. and Pierre Fabre SA announced the approval of Tabelecleucel, a therapy for a rare and potentially fatal malignancy. more ➔
financingNumares AG cashes in €20m from EIBThe European Investment Bank (EIB) is going to support the AI-platform of NMR/metabolomics diagnostics company Numares AG to improve disease prediction. more ➔
INDUSTRIA BIOTEC 2023 with a broader persp..."Solutions for an endangered planet" is what industrial biotechnology seeks and offers. Technical innovations based on nature’s toolbox are intended to help "biologise" industry – … more ➔
AMR€72M from Novo´s REPAIR Impact Fund for...MinervaX inks €72m financing deal with Novo Holdings REPAIR Impact Fund to develop a vaccine against Group B Streptococcus. more ➔
A ray of hope in leukaemiaA child with recurrent T-cell leukaemia was given base-edited T-cells in a world-first application of a base-edited cell therapy. more ➔
Amgen wins race of top `22 deals with $26b...According to Bloomberg, the US biotechnology giant Amgen plans to buy Horizon Therapeutics at a valuation of about $26bn. Overall, the deal corresponds to an enterprise value including debt of $28.3bn. … more ➔
